Zyflo CR Related Published Studies
Well-designed clinical trials related to Zyflo CR (Zileuton)
Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. [2011.02]
Randomized trial of zileuton for treatment of COPD exacerbations requiring
hospitalization. [2011]
Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. [2007.08]
Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. [2007.06]
The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. [2007.05]
Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. [2007]
Effects of 5-lipoxygenase inhibitor zileuton on airway responses to inhaled swine house dust in healthy subjects. [2006.02]
Double-blinded, placebo-controlled, cross-over pilot study on the efficacy of zileuton for canine atopic dermatitis. [2001.08]
Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. [2000.04]
Safety and clinical efficacy of zileuton in patients with chronic asthma. [1998.06]
The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma. [1998.05]
Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. [1998.04]
A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group. [1998.01.26]
Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids. [1997.12]
Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers. [1997.05]
Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. [1997.04]
A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. [1997.03]
The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. [1997]
Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. [1996.11]
Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. [1996.03.27]
Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. [1996.03]
A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. [1996.02]
A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus. [1995.03]
The effect of zileuton on antipyrine and indocyanine green disposition. [1995.03]
Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans. [1995]
The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers. [1995]
Lack of pharmacokinetic interaction between zileuton and phenytoin in humans. [1995]
Effect of zileuton on theophylline pharmacokinetics. [1995]
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. [1993.12.01]
Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. [1992.10]
Effect of Zileuton (A-64077) on the 5-lipoxygenase activity of human whole blood ex vivo. [1991.09]
Well-designed clinical trials possibly related to Zyflo CR (Zileuton)
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. [2008.02.20]
The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude. [2005.02]
Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma. [2004.03]
Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma. [2000.09]
Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. [1995.10]
Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. [1995.09]
Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor. [1995.07]
Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase pathway. [1995.05]
Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis. [1995]
Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. [1994.12]
The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. [1993.12]
5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. [1992]
Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. [1991.03]
Other research related to Zyflo CR (Zileuton)
Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. [2009.12]
5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. [2009.10]
Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250mug/Salmeterol 50mug. [2009.05.23]
Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. [2007.06]
Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. [2007.04]
Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. [2000.07]
Other possibly related research studies
Pharmacological intervention to the inflammatory response from decompression sickness in rats. [2008.02]
Gateways to clinical trials. [2007.12]
Role of long-acting beta2-adrenergic agonists in asthma management based on updated asthma guidelines. [2008.01]
Effect of dexamethasone associated with serum therapy on treatment of Bothrops jararaca venom-induced paw edema in mice. [2007.10]
Effects of leukotriene inhibition on pulmonary morphology in rat pup lungs exposed to hyperoxia. [2007.04]
Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. [2007]
Licofelone--a novel analgesic and anti-inflammatory agent. [2007]
Leukotriene inhibitors in the treatment of allergy and asthma. [2007.01.01]
Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation. [2007.05]
Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. [2007.07]
Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. [2008.10.15]
Gateways to clinical trials. [2008.05]
Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. [2009.08]
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. [2009.08]
5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. [2009.03]
Leukotriene pathways and in vitro adenotonsillar cell proliferation in children with obstructive sleep apnea. [2009.05]
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. [2008.11.15]
Synthesis and pharmacological evaluation of 2-substituted benzo[b]thiophenes as anti-inflammatory and analgesic agents. [2009.04]
Systemic therapies in managing sinonasal inflammation. [2010.06]
Antileukotriene drugs in the treatment of asthma. [2010.03]
Metabolomics in drug intolerance. [2009.11]
Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry. [2010.02.01]
Targeting Ca2+ release-activated Ca2+ channel channels and leukotriene receptors provides a novel combination strategy for treating nasal polyposis. [2009.11]
When surgery, antibiotics, and steroids fail to resolve chronic rhinosinusitis. [2009.11]
The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. [2009.11.01]
Induction of leukotriene B(4) and prostaglandin E(2) release from keratinocytes by protease-activated receptor-2-activating peptide in ICR mice. [2009.10]
CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain. [2009.09.01]
Association between leukotriene-modifying agents and suicide: what is the evidence? [2011.07.01]
5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids. [2011.02.09]
Pranlukast attenuates hydrogen peroxide-induced necrosis in endothelial cells by inhibiting oxygen reactive species-mediated collapse of mitochondrial membrane potential. [2011.04]
The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field. [2010]
Pharmacological characterization of itch-associated response induced by repeated application of oxazolone in mice. [2010]
Hyperalgesic and edematogenic effects of peptides isolated from the venoms of honeybee (Apis mellifera) and neotropical social wasps (Polybia paulista and Protonectarina sylveirae). [2011.01]
CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung
cancer in a prospective trial: CALGB 150304. [2012]
|
